Last reviewed · How we verify
NCT07205575
AI-Guided Proteomic Biomarker Panel for Differentiating Bacterial and Viral Infections in Acute Febrile Illness
trial testing Proteomic Biomarker Panel in Acute Febrile Illness in 394 participants. Completed in 30 November 2024.
31 October 2024
Quick facts
| Lead sponsor | Qilu Hospital of Shandong University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 394 |
| Start date | 1 September 2021 |
| Primary completion | 31 October 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Proteomic Biomarker Panel
Conditions studied
- Acute Febrile Illness — all drugs for Acute Febrile Illness →
- Bacterial Infections — all drugs for Bacterial Infections →
- Viral Infections — all drugs for Viral Infections →
- Sepsis — all drugs for Sepsis →
Sponsor
Qilu Hospital of Shandong University
Who can join
14 and older, any sex, with Acute Febrile Illness or Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a proteomics-based diagnostic biomarker study conducted on the same patient cohort as the transcriptomic biomarker study (NCT065529754). Although both studies share the same clinical cohort and overarching diagnostic aim, they are registered separately because they employ distinct omics technologies, investigate different biomarker modalities, and yield independent outcome measures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07205575
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Febrile Illness
Currently open trials in the same condition.
- NCT06822907 — Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults · Phase 4 · recruiting
- NCT04629053 — Causes and Outcomes of Febrile Illness in Health Facilities in Rural South and Southeast Asia · recruiting
Other Qilu Hospital of Shandong University trials
Trials by the same sponsor.
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
- NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
- NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
- NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
- NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07205575 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
- Last refreshed: 3 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07205575.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing